Showing results (111-120 of 388) with videos related to

Sort By:
Pageof 39
Endocrine-Related Cancer|September 17, 2013
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotateKimberly Kamp, Brenda Gumz, Richard A Feelders, et al.
Life Sciences|January 1, 1989
On the enterohepatic cycle of triiodothyronine in rats; importance of the intestinal microfloraW W de Herder, M P Hazenberg, A M Pennock-Schröder, et al.
Cancers|July 27, 2022
Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor MicroenvironmentThomas Cuny, Peter M van Koetsveld, Grégoire Mondielli, et al.
The Netherlands Journal of Medicine|September 1, 1996
An unusual case of multiple endocrine neoplasia type 1 and the role of 111In-pentetreotide scintigraphyH H Ponssen, W W de Herder, H J Bonjer, et al.
Frontiers in Neuroendocrinology|January 1, 1993
Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphyS W Lamberts, L J Hofland, W W de Herder, et al.
European Journal of Endocrinology|December 1, 1994
Serum chromogranin A in the differential diagnosis of Cushing's syndromeF R Nobels, W W de Herder, D J Kwekkeboom, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2007
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidneyEdgar J Rolleman, Peter P M Kooij, Wouter W de Herder, et al.
Hematology/Oncology Clinics of North America|June 6, 2007
Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analoguesDik J Kwekkeboom, Jaap J M Teunissen, Boen L Kam, et al.
Endocrine|December 15, 2010
Effects of thyroid status and thyrostatic drugs on hepatic glucuronidation of lodothyronines and other substrates in rats : Induction of phenol UDP-glucuronyltransferase by methimazoleT J Visser, E Kaptein, A Gijzel, et al.
Clinical Endocrinology|October 1, 1995
IGFBP-3 is a poor parameter for assessment of clinical activity in acromegalyW W de Herder, A J van der Lely, J A Janssen, et al.
Pageof 39